公开(公告)号：US5763199A

公开(公告)日：1998-06-09

申请号：US315026

申请日：1994-09-29

申请人： Barry Coller

发明人： Barry Coller

IPC分类号： G01N33/50 ,  G01N33/86 ,  G01N33/546 ,  G01N33/552

CPC分类号： G01N33/86 ,  G01N33/5091 ,  Y10S435/975

摘要： The present invention is an assay for determining glycoprotein IIb/IIIa receptor blockade in whole blood. Agglutinization of small polymeric beads coated with a glycoprotein IIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein IIb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade of the GPIIb/IIIa receptors has been achieved. In a preferred embodiment, the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the glycoprotein IIb/IIIa receptors are not blocked.

摘要翻译： 本发明是用于测定全血中糖蛋白IIb / IIIa受体阻断的测定方法。 当珠粒与含有未被阻断的糖蛋白IIb / IIIa受体的全血血小板接触时，会结合涂有糖蛋白IIb / IIIa配体如纤维蛋白原的小聚合物珠粒的凝集。 未凝聚表明GPIIb / IIIa受体的阻断已经实现。 在优选的实施方案中，加入凝血酶受体激活剂导致快速和方便的测定，以便在床边进行，并且如果糖蛋白IIb / C的结合导致小聚合物珠粒在方便的已知时间段内凝集， IIIa受体不被阻断。

公开(公告)号：US09506938B2

公开(公告)日：2016-11-29

申请号：US12598581

申请日：2008-05-01

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： G01N33/86

CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

摘要： A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

摘要翻译： 提供了用于测量用药物洗脱支架（DES）处理的个体中血小板反应性抑制的方法。 首先，从用DES和P2Y12拮抗剂处理的个体获得血液样品。 然后将血液样品与包含附着的GPIIb / IIIa受体配体，二磷酸腺苷（ADP）和前列腺素E1（PGE1）的颗粒混合。 将混合物在适合于凝集颗粒的条件下孵育，并在混合物中评估血小板介导的凝集。 凝集的不存在或减少表明用DES处理的个体降低了血小板反应性。 还提供了一种用于测量P2Y12受体拮抗剂抑制血小板聚集的试剂盒，其包括固定在颗粒上的GPIIb / IIIa受体配体，二磷酸腺苷（ADP），前列腺素E1（PGE1），抗凝血剂和缓冲液，以维持 抗凝血液适合血小板聚集。

公开(公告)号：US20100184084A1

公开(公告)日：2010-07-22

申请号：US12598581

申请日：2008-05-01

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： G01N33/53

CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

摘要： A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

摘要翻译： 提供了用于测量用药物洗脱支架（DES）处理的个体中血小板反应性抑制的方法。 首先，从用DES和P2Y12拮抗剂处理的个体获得血液样品。 然后将血液样品与包含附着的GPIIb / IIIa受体配体，二磷酸腺苷（ADP）和前列腺素E1（PGE1）的颗粒混合。 将混合物在适合于凝集颗粒的条件下孵育，并在混合物中评估血小板介导的凝集。 凝集的不存在或减少表明用DES处理的个体降低了血小板反应性。 还提供了用于测量P2Y12受体拮抗剂抑制血小板聚集的试剂盒，其包括固定在颗粒上的GPIIb / IIIa受体配体，二磷酸腺苷（ADP），前列腺素E1（PGE1），抗凝血剂和缓冲液，以维持 抗凝血液适合血小板聚集。

公开(公告)号：US20050031616A1

公开(公告)日：2005-02-10

申请号：US10886155

申请日：2004-07-06

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： A61K31/557 ,  A61K39/395 ,  A61K49/00 ,  C12Q20060101 ,  C12Q1/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/86

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

摘要翻译： 提供一种确定个体是否由于抑制血小板活化起始，信号转导和/或GPIIb / IIIa阻断而形成血小板血栓形成能力降低的方法。 从被评估的个体获得血液样本。 血液样品与1）抗凝剂混合; 2）足够的缓冲液将抗凝血液的pH和盐浓度保持在适合血小板聚集的范围内; 3）固定在固体表面上的血小板GPIIb / IIIa受体配体; 4）增强信号转导途径的一种或多种药物和5）受体激活剂。 将该组合在凝集颗粒的条件下孵育。 在搅拌的混合物中评估血小板介导的凝集。 没有凝集表明个体具有降低形成血小板血栓的能力。

公开(公告)号：US20070243632A1

公开(公告)日：2007-10-18

申请号：US11742684

申请日：2007-05-01

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： G01N33/50

CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

摘要： A method is providing for measuring platelet reactivity of a PCI patient that has a (DES). A blood sample is obtained from the patient. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.

摘要翻译： 一种测量具有（DES）的PCI患者的血小板反应性的方法。 从患者获得血液样本。 血液样品与1）抗凝剂混合; 2）足够的缓冲液将抗凝血液的pH和盐浓度保持在适合血小板聚集的范围内; 3）固定在固体表面上的血小板GPIIb / IIIa受体配体; 4）增强信号转导途径的一种或多种药物和5）受体激活剂。 将该组合在凝集颗粒的条件下孵育。 在混合物中评估血小板介导的凝集。 没有凝集表明患者形成血小板血栓形成能力下降。

公开(公告)号：US20050112124A1

公开(公告)日：2005-05-26

申请号：US10980496

申请日：2004-11-03

申请人： Paul Frenette ,  Barry Coller ,  Aslihan Turhan

发明人： Paul Frenette ,  Barry Coller ,  Aslihan Turhan

IPC分类号： C07K16/24 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/2839 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/2851

摘要： The present invention relates to methods of treating sickle cell disease comprising reducing, in a subject in need of such treatment, the adherence between sickle RBCs and leukocytes. It is based, at least in part, on the discovery that leukocytes play a direct role in the initiation of venular occlusion. The present invention further provides for methods for identifying agents which decrease SS-RBC/leukocyte adherence and for animal models which may be used to further elucidate the mechanism of vaso-occlusion in sickle cell crises.

摘要翻译： 本发明涉及治疗镰状细胞疾病的方法，包括在需要这种治疗的受试者中减少镰状红细胞和白细胞之间的粘附。 至少部分地基于白细胞在起始静脉闭塞中起直接作用的发现。 本发明还提供了用于鉴定降低SS-RBC /白细胞粘附的试剂的方法，以及可用于进一步阐明镰状细胞危象中血管闭塞机制的动物模型的方法。